Literature DB >> 17909121

Absence of peroxisome proliferator-activated receptor-alpha abolishes hypertension and attenuates atherosclerosis in the Tsukuba hypertensive mouse.

Karen M Tordjman1, Clay F Semenkovich, Trey Coleman, Rachel Yudovich, Stella Bak, Etty Osher, Michal Vechoropoulos, Naftali Stern.   

Abstract

Peroxisome proliferator-activated receptor-alpha is widely distributed in the vasculature where it is believed to exert pleiotropic antiatherogenic effects. Its role in the regulation of blood pressure is still unresolved; however, some evidence suggests that it may affect the renin-angiotensin system. We investigated its role in angiotensin II-induced hypertension in the Tsukuba hypertensive mouse (THM). This is a model of hypertension and atherosclerosis because of high angiotensin II and aldosterone levels as a result of the transgenic expression of the entire human renin-angiotensin system. Making the THM animals deficient in Peroxisome proliferator-activated receptor-alpha (THM/PPARKO) totally abolished hypertension and myocardial hypertrophy. This was accompanied by a reduction in plasma human active renin in THM/PPARKO mice compared with THM animals from 3525+/-128 mU/L to 1910+/-750 mU/L (P<0.05) and by a normalization of serum aldosterone (1.6+/-0.29 nmol/L versus 3.4+/-0.69 nmol/L; P=0.003). In the THM/PPARKO mice, the extent of atherosclerosis at the aortic sinus after a 12-week period on an atherogenic diet was decreased by >80%. In addition, the spontaneous formation of foam cells from peritoneal macrophages, a blood pressure-independent event, was reduced by 92% in the THM/PPARKO mice, suggesting protection from the usual oxidative stress in these animals, possibly because of lower prevailing angiotensin II levels. Finally, chronic fenofibrate treatment further elevated blood pressure in THM animals but not in THM/PPARKO animals. Taken together, these data indicate that peroxisome proliferator-activated receptor-alpha may regulate the renin-angiotensin system. They raise the possibility that its activation may aggravate hypertension and hasten atherosclerosis in the context of an activated renin-angiotensin system.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17909121     DOI: 10.1161/HYPERTENSIONAHA.107.094268

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  10 in total

Review 1.  The peroxisome proliferator-activated receptors in cardiovascular diseases: experimental benefits and clinical challenges.

Authors:  Wai San Cheang; Xiao Yu Tian; Wing Tak Wong; Yu Huang
Journal:  Br J Pharmacol       Date:  2015-01-23       Impact factor: 8.739

2.  Peroxisome proliferator-activated receptor-alpha gene level differently affects lipid metabolism and inflammation in apolipoprotein E2 knock-in mice.

Authors:  Fanny Lalloyer; Kristiaan Wouters; Morgane Baron; Sandrine Caron; Emmanuelle Vallez; Jonathan Vanhoutte; Eric Baugé; Ronit Shiri-Sverdlov; Marten Hofker; Bart Staels; Anne Tailleux
Journal:  Arterioscler Thromb Vasc Biol       Date:  2011-04-07       Impact factor: 8.311

3.  Oxidative stress promotes myocardial fibrosis by upregulating KCa3.1 channel expression in AGT-REN double transgenic hypertensive mice.

Authors:  Li-Ping Wang; Su-Jing Fan; Shu-Min Li; Xiao-Jun Wang; Jun-Ling Gao; Xiu-Hong Yang
Journal:  Pflugers Arch       Date:  2017-04-28       Impact factor: 3.657

4.  PPARs in the Renal Regulation of Systemic Blood Pressure.

Authors:  Tamás Roszer; Mercedes Ricote
Journal:  PPAR Res       Date:  2010-06-08       Impact factor: 4.964

Review 5.  PPARs are a unique set of fatty acid regulated transcription factors controlling both lipid metabolism and inflammation.

Authors:  Tamas Varga; Zsolt Czimmerer; Laszlo Nagy
Journal:  Biochim Biophys Acta       Date:  2011-03-05

Review 6.  Regulation of Nox enzymes expression in vascular pathophysiology: Focusing on transcription factors and epigenetic mechanisms.

Authors:  Simona-Adriana Manea; Alina Constantin; Gina Manda; Shlomo Sasson; Adrian Manea
Journal:  Redox Biol       Date:  2015-06-25       Impact factor: 11.799

7.  Effects of CP-900691, a novel peroxisome proliferator-activated receptor α, agonist on diabetic nephropathy in the BTBR ob/ob mouse.

Authors:  Bardia Askari; Tomasz Wietecha; Kelly L Hudkins; Edward J Fox; Kevin D O'Brien; Jinkyu Kim; Tri Q Nguyen; Charles E Alpers
Journal:  Lab Invest       Date:  2014-06-23       Impact factor: 5.662

8.  Mechanistic insights into cardiovascular protection for omega-3 fatty acids and their bioactive lipid metabolites.

Authors:  Timothy D O'Connell; Richard Preston Mason; Matthew J Budoff; Ann Marie Navar; Gregory C Shearer
Journal:  Eur Heart J Suppl       Date:  2020-10-06       Impact factor: 1.803

9.  Hemodynamic effects of fenofibrate and coenzyme Q10 in type 2 diabetic subjects with left ventricular diastolic dysfunction.

Authors:  Gerard T Chew; Gerald F Watts; Timothy M E Davis; Bronwyn G A Stuckey; Lawrence J Beilin; Peter L Thompson; Valerie Burke; Philip J Currie
Journal:  Diabetes Care       Date:  2008-05-16       Impact factor: 19.112

10.  The Proatherogenic Effect of Chronic Nitric Oxide Synthesis Inhibition in ApoE-Null Mice Is Dependent on the Presence of PPAR α.

Authors:  Michal Vechoropoulos; Maya Ish-Shalom; Sigal Shaklai; Jessica Sack; Naftali Stern; Karen M Tordjman
Journal:  PPAR Res       Date:  2014-01-22       Impact factor: 4.964

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.